Buscador de publicaciones<< Volver

Cases A, Portolés J, Calls J, Martínez-Castelao A, Munar MA, Segarra A

Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA Study.

Int Urol Nephrol. 2014 Oct;46(10):1983-95, PMID: 25118611

To assess whether the correction dose recommended by the summary of product characteristics was adequate and to confirm the adequacy of the recommended conversion dosing strategies from shorter-acting erythropoiesis-stimulating agents (ESAs) to continuous erythropoietin receptor activator (C.E.R.A) in anaemic chronic kidney disease (CKD) patients in the clinical setting.


Descargar la publicación

Una iniciativa de

Ministerio de Economía y Competitividad Fondo Europeo de Desarrollo Regional IMIM - Parc de Salut Mar